Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study
2019
AbstractThis multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
23
References
11
Citations
NaN
KQI